Charles Schwab Investment Management Inc. Has $1.44 Million Holdings in ProKidney Corp. (NASDAQ:PROK)

Charles Schwab Investment Management Inc. grew its holdings in shares of ProKidney Corp. (NASDAQ:PROK - Free Report) by 150.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 749,718 shares of the company's stock after buying an additional 450,548 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.26% of ProKidney worth $1,439,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in ProKidney by 44.6% during the second quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company's stock valued at $441,000 after buying an additional 55,266 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of ProKidney by 8.8% in the 2nd quarter. Rhumbline Advisers now owns 76,190 shares of the company's stock valued at $187,000 after acquiring an additional 6,181 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of ProKidney during the 2nd quarter valued at approximately $124,000. AQR Capital Management LLC bought a new position in ProKidney during the second quarter worth $50,000. Finally, The Manufacturers Life Insurance Company acquired a new position in ProKidney in the second quarter worth $60,000. Institutional investors and hedge funds own 51.59% of the company's stock.

Analyst Ratings Changes

PROK has been the topic of several research reports. Guggenheim started coverage on shares of ProKidney in a research note on Tuesday, September 10th. They set a "buy" rating and a $6.00 price objective on the stock. JPMorgan Chase & Co. started coverage on ProKidney in a research report on Monday, September 30th. They set a "neutral" rating on the stock. Finally, Bank of America reduced their price objective on ProKidney from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, ProKidney has an average rating of "Hold" and an average target price of $4.50.

ProKidney Trading Up 0.5 %

Shares of PROK traded up $0.01 during midday trading on Tuesday, hitting $1.85. The stock had a trading volume of 464,778 shares, compared to its average volume of 686,688. ProKidney Corp. has a fifty-two week low of $1.18 and a fifty-two week high of $4.44. The business has a 50-day simple moving average of $1.85 and a two-hundred day simple moving average of $2.18. The firm has a market cap of $539.57 million, a P/E ratio of -3.33 and a beta of 1.27.

ProKidney (NASDAQ:PROK - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). On average, analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Darin J. Weber sold 16,412 shares of ProKidney stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $2.50, for a total transaction of $41,030.00. Following the completion of the sale, the insider now directly owns 103,480 shares in the company, valued at $258,700. The trade was a 13.69 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 41.49% of the stock is currently owned by corporate insiders.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.